The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Agios; Bayer; Celgene; Novartis; Pfizer
Research Funding - Agios; Celgene; Novartis
Travel, Accommodations, Expenses - Celgene
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Anthony Selwyn Stein
Speakers' Bureau - Amgen; Celgene
 
Eytan M. Stein
No Relationships to Disclose
 
Amir Tahmasb Fathi
Honoraria - Agios; Baxalta; Merck; Seagen; Tolero Pharmaceuticals
Research Funding - Celgene (Inst); Exelixis (Inst); Seagen (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Agios
 
Andre C. Schuh
Honoraria - Agios; Amgen; Celgene
Consulting or Advisory Role - Agios; Amgen; Celgene
 
Pau Montesinos Fernández
Research Funding - Celgene; Novartis; Pfizer
 
Olatoyosi Odenike
Consulting or Advisory Role - Abbvie; CTI/Baxalta; Jazz Pharmaceuticals; Pfizer
Research Funding - Abbvie (Inst); Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); MEI Pharma (Inst); Millennium (Inst); NS Pharma (Inst); OncoTherapy Science (Inst)
 
Hagop M. Kantarjian
Research Funding - Amgen; ARIAD; Astex Pharmaceuticals; Bristol-Myers Squibb; Novartis; Pfizer
 
Richard M. Stone
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bristol-Myers Squibb; Celator; Celgene; Fujifilm; Juno Therapeutics; Karyopharm Therapeutics; Merck; Novartis; Ono Pharmaceutical; Roche/Genentech; Theradex
Research Funding - Agios (Inst); Celator (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Robert Collins
Employment - University of Texas Southwestern Medical Center - Simmons Cancer Center
Honoraria - OptumHealth
Research Funding - Agios; Arog; Bristol-Myers Squibb; Celgene
 
Giovanni Martinelli
Consulting or Advisory Role - Abbvie; ARIAD/Incyte; Johnson & Johnson; Pfizer; Roche
 
Montserrat Arnan
No Relationships to Disclose
 
Bin Wu
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Daniel O. Koralek
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Jason Van Oostendorp
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Jing Gong
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Kyle J. MacBeth
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Patents, Royalties, Other Intellectual Property - Several patents and patent applications for composition and uses of drugs for oncology indications
Travel, Accommodations, Expenses - Celgene
 
Paresh Vyas
Honoraria - Celgene; Novartis
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Becton Dickinson
Travel, Accommodations, Expenses - Celgene; Novartis